Abstracts tagged "CNS Lupus and SLE"

Abstract Number: 937 • 2018 ACR/ARHP Annual Meeting
Evidence of a Common Microglial Signature in Models of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Hadijat M. Makinde¹, Elise V. Mike², Deborah R. Winter³, Chaim Putterman⁴ and Carla M. Cuda³, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Albert Einstein College of Medicine, Bronx, NY, ³Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune syndrome affecting multiple organs, including the brain. More than 60% of patients experience neuropsychiatric symptoms of…
Abstract Number: 1852 • 2015 ACR/ARHP Annual Meeting
Association of Antibodies to the NR1 Subunit of N-Methyl-D-Aspartate Receptors with Neuropsychiatric Systemic Lupus Erythematosus
Eisuke Ogawa¹, Tatsuo Nagai², Yuko Sakuma³, Yoshiyuki Arinuma⁴ and Shunsei Hirohata⁴, ¹Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ²Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁴Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: To explore the roles of autoantibodies to N-methyl-D-aspartate (NMDA) receptor NR1 subunit in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE).Methods: Paired serum and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].